Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line

Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03288298

Enrollment

Registered

2017-09-20

Start date

2017-11-01

Completion date

2019-04-01

Last updated

2017-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Tongue Neoplasms

Keywords

TSCC, OSCC, luteolin, nanoluteolin, nanotechnology, oral cancer, apoptosis, PCR, MTT, ELISA reader

Brief summary

In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line.

Detailed description

This study is conducted to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line. The primary outcome is apoptosis, while the secondary outcome is cell viability.

Interventions

DRUGluteolin

flavonoid natural extract

DRUGnano-luteolin

nanoparticles of luteolin

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Squamous cell carcinoma cell lines (OSCC, TSCC and HNSCC). * Luteolin 5,7,3',4'-tetrahydroxy-flavone (MeSH term). * Application of luteolin as a chemotherapeutic drug.

Exclusion criteria

* Any cancer cell line other than OSCC, TSCC and HNSCC cell lines. * Luteolin glycosides.

Design outcomes

Primary

Measure	Time frame	Description
gene expression of Caspase 3 to detect apoptosis	6 hours	fold-changes

Secondary

Measure	Time frame	Description
cell viability	6 hours	micromolar

Contacts

Primary ContactSafaa M. Baz, Masters

drsafaaelbaz@gmail.com002 01119777824

Backup ContactSafa F. Abd El-Ghani, PhD

drsafa.fathy@yahoo.com002 01005198010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026